Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus mitotane versus mitotane in advanced adrenal cortical carcinoma
ChiCTR2500099472Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab and mitotane in adrenal cancer (ACC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: 1-year progression-free survival rate, Overall survival and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
toripalimabmitotane
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on ChiCTR2500099472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099472.